SLDB Solid Biosciences Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1707502 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-28.8%
TTM EPS YoY29.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-76.9%
ROA-64.9%
ROIC (approx.)-94.0%
Asset turnover—
Leverage & solvency
Liabilities / assets12.3%
Debt / equity0.00x
Current ratio11.99x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.92x
Accruals ratio-4.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q3*2026-09-30 | 2026Q2*2026-06-30 | 2026Q1*2026-03-31 | 2025Q4*2025-12-31 | 2025Q3*2025-09-30 | 2025Q2*2025-06-30 | 2025Q1*2025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $43.59M | $44.27M | $46.14M | $38.13M | $38.86M | $32.41M | $30.91M | $30.77M |
| SG&A expense | $14.06M | $13.12M | $11.17M | $11.27M | $9.20M | $9.28M | $9.14M | $9.13M |
| Operating income | -$57.66M | -$57.38M | -$57.31M | -$49.40M | -$48.06M | -$41.69M | -$40.05M | -$39.90M |
| Interest expense | — | — | — | $5,000 | -$336,000 | $60,000 | $68,000 | $75,000 |
| Net income | -$53.95M | -$54.80M | -$56.74M | -$49.79M | -$45.78M | -$39.48M | -$39.28M | -$42.60M |
| EBITDA | -$57.24M | -$56.99M | -$56.91M | -$48.94M | -$47.68M | -$41.31M | -$39.65M | -$39.41M |
| EPS (basic) | -0.36 | -0.38 | -0.52 | — | -0.48 | -0.42 | -0.59 | — |
| EPS (diluted) | -0.36 | -0.38 | -0.52 | — | -0.48 | -0.42 | -0.59 | — |
| Weighted avg. shares (diluted) | 151.03M | 143.69M | 109.81M | — | 94.42M | 94.14M | 66.34M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $125.97M | $159.39M | $297.10M | $59.90M | $61.36M | $138.93M | $210.63M | $82.19M |
| Short-term investments | $222.96M | $218.28M | $83.58M | $127.95M | $174.78M | $129.18M | $96.29M | $68.69M |
| Current assets | $365.19M | $395.11M | $396.79M | $205.46M | $244.85M | $278.64M | $313.41M | $157.30M |
| PP&E, net | $3.73M | $3.96M | $3.91M | $4.17M | $4.36M | $4.32M | $4.48M | $4.75M |
| Total assets | $389.90M | $420.58M | $422.89M | $232.54M | $273.91M | $308.29M | $343.90M | $188.66M |
| Current liabilities | $30.45M | $28.58M | $30.28M | $33.47M | $36.34M | $29.85M | $28.78M | $30.26M |
| Total liabilities | $47.79M | $46.51M | $48.76M | $52.53M | $55.97M | $50.00M | $49.44M | $51.42M |
| Shareholders' equity | $342.11M | $374.07M | $374.13M | $180.01M | $217.95M | $258.29M | $294.46M | $137.25M |
| Shares outstanding | 111.56M | 105.13M | 98.39M | 78.97M | 77.88M | 77.60M | 77.49M | 40.47M |
| Cash flow statement | ||||||||
| Operating cash flow | -$45.55M | -$52.59M | -$47.23M | -$53.55M | -$33.47M | -$37.41M | -$31.85M | -$29.64M |
| Capital expenditure | $498,000 | $150,000 | $165,000 | $565,000 | $85,000 | $377,000 | $126,000 | $204,000 |
| Free cash flow | -$46.04M | -$52.74M | -$47.40M | -$54.12M | -$33.56M | -$37.79M | -$31.98M | -$29.85M |
| Investing cash flow | -$3.76M | -$133.59M | $44.76M | $47.01M | -$45.27M | -$32.73M | -$27.46M | $38.57M |
| Financing cash flow | $15.88M | $48.47M | $239.03M | $5.14M | $1.18M | -$1.60M | $189.73M | $6.94M |
| Depreciation & amortization | $416,000 | $391,000 | $395,000 | $467,000 | $376,000 | $386,000 | $407,000 | $488,000 |
| Stock-based compensation | $6.15M | $5.62M | $5.15M | $6.50M | $3.93M | $3.15M | $3.34M | $3.82M |
Free plan shows the latest 8 periods; Pro shows all 39 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.